Health effects of the New Nordic Renal Diet in patients with stage 3 and 4 chronic kidney disease, compared with habitual diet: a randomized trial.

24h urine phosphorus New Nordic Renal Diet acid base blood pressure chronic kidney disease dietary intervention low dietary protein low dietary sodium metabolic syndrome proteinuria weight loss

Journal

The American journal of clinical nutrition
ISSN: 1938-3207
Titre abrégé: Am J Clin Nutr
Pays: United States
ID NLM: 0376027

Informations de publication

Date de publication:
11 2023
Historique:
received: 26 04 2023
revised: 14 08 2023
accepted: 16 08 2023
medline: 6 11 2023
pubmed: 21 8 2023
entrez: 20 8 2023
Statut: ppublish

Résumé

Chronic kidney disease (CKD) leads to an accumulation of waste products and causes adverse cardiometabolic effects. We investigated the health effects of the New Nordic Renal Diet (NNRD), a novel meal pattern reduced in phosphorus, protein, and sodium. A 26-wk randomized trial compared the NNRD with a habitual diet. The NNRD group received weekly home deliveries of food and recipes. Monthly study visits included fasting blood samples, 24-h urine samples, blood pressure, and anthropometric measurements. Intention-to-treat analysis used linear mixed-effects models. Sixty patients, mean estimated glomerular filtration rate (eGFR) 34 mL/min/1.73 m NNRD in moderate CKD reduces phosphorus excretion, proteinuria, systolic blood pressure, and weight, mainly by reducing abdominal fat. This trial was registered at clinicaltrials.gov as NCT04579315.

Sections du résumé

BACKGROUND
Chronic kidney disease (CKD) leads to an accumulation of waste products and causes adverse cardiometabolic effects.
OBJECTIVES
We investigated the health effects of the New Nordic Renal Diet (NNRD), a novel meal pattern reduced in phosphorus, protein, and sodium.
METHODS
A 26-wk randomized trial compared the NNRD with a habitual diet. The NNRD group received weekly home deliveries of food and recipes. Monthly study visits included fasting blood samples, 24-h urine samples, blood pressure, and anthropometric measurements. Intention-to-treat analysis used linear mixed-effects models.
RESULTS
Sixty patients, mean estimated glomerular filtration rate (eGFR) 34 mL/min/1.73 m
CONCLUSION
NNRD in moderate CKD reduces phosphorus excretion, proteinuria, systolic blood pressure, and weight, mainly by reducing abdominal fat. This trial was registered at clinicaltrials.gov as NCT04579315.

Identifiants

pubmed: 37598748
pii: S0002-9165(23)66078-2
doi: 10.1016/j.ajcnut.2023.08.008
pii:
doi:

Substances chimiques

Sodium 9NEZ333N27
Phosphorus 27YLU75U4W

Banques de données

ClinicalTrials.gov
['NCT04579315']

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1042-1054

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Nikita Misella Hansen (N)

Department of Nephrology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Electronic address: nikita.misella.hansen@gmail.com.

Anne-Lise Kamper (AL)

Department of Nephrology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

Marianne Rix (M)

Department of Nephrology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

Bo Feldt-Rasmussen (B)

Department of Nephrology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.

Jens Leipziger (J)

Department of Biomedicine, Aarhus University, Aarhus, Denmark.

Mads Vaarby Sørensen (MV)

Department of Biomedicine, Aarhus University, Aarhus, Denmark.

Peder Berg (P)

Department of Biomedicine, Aarhus University, Aarhus, Denmark.

Arne Astrup (A)

Department of Obesity and Nutritional Sciences, Novo Nordisk Foundation, Hellerup, Denmark.

Louise Salomo (L)

Department of Nephrology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH